Robert Cooper, MD
Endocrinology, Diabetes & Metabolism · Holyoke, MANPI 1992739726
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,720 of the $106,266 with a category attached, or 70.3%. It is spread thinly across 48 manufacturers, the largest accounting for just 23.3%. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $230.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$25K
- Abbott$21K
- Amgen$18K
- Lilly USA, LLC$13K
- Shire North American Group Inc$11K
- Bayer$3K
- plus $15K from 42 others
What the payments were for
- Consulting fees$11,95211%
- Speaking & faculty fees$74,72070%
- Travel & lodging$9,1059%
- Food & beverage$10,38710%
- Education$420%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$20,639
- Yorvipath$19,421
- NATPARA (PARATHYROID HORMONE)$11,126
- Prolia$10,458
- MOUNJARO$9,796
- Kerendia$3,154
- TEPEZZA$1,320
- EVENITY$1,024
- INVOKANA$845
- MYCAPSSA$700
- t:slim X2 insulin pump$400
- SOLIQUA 100/33$375
- Minimed 670G System$171
- SKYTROFA$129
- AFREZZA$115
- TOUJEO$110
- DEXCOM G6 TRANSMITTER$101
How this compares
$106,266 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 268 | $315,228 |
| TrulicityDulaglutide | 256 | $268,808 |
| TymlosAbaloparatide | 92 | $250,722 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 87 | $214,034 |
| OzempicSemaglutide | 141 | $137,279 |
| JardianceEmpagliflozin | 179 | $119,258 |
| Tresiba Flextouch U-200Insulin Degludec | 119 | $80,133 |
| ProliaDenosumab | 31 | $52,265 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $48,213 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $47,963 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $40,036 |
| Humulin R U-500Insulin Regular, Human | 24 | $37,913 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $35,215 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $32,486 |
| FarxigaDapagliflozin Propanediol | 52 | $31,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $13,007 | $584,036524 claims |
| AmgenEvenity (2 Syringes), Prolia | $17,999 | $266,299118 claims |
| Radius Health, Inc.Tymlos | $364 | $250,72292 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,070 | $166,440207 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $311 | $141,369207 claims |
| AstraZenecaFarxiga | $2,062 | $31,34452 claims |
| MerckJanuvia | $51 | $11,56217 claims |
| AbbVieSynthroid | $422 | $5,16273 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $2,464311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Holyoke
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.